

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Phosphorylation of Anti-HIV Nucleoside Analogs by Nucleoside Diphosphate Kinase

Benoit Schneider<sup>a</sup>; Yingwu Xu<sup>b</sup>; Olivier Sellam<sup>a</sup>; Robert Sarfati<sup>c</sup>; Joel Janin<sup>b</sup>; Michel Véron<sup>a</sup>; Dominique Deville-bonne<sup>a</sup>

<sup>a</sup> Unité de Régulation Enzymatique des Activités Cellulaires, CNRS URA 1773, Institut Pasteur, Paris, France <sup>b</sup> Laboratoire d'Enzymologie et de Biochimie Structurales, Gif-sur-Yvette, France <sup>c</sup> Unité de Chimie Organique, Institut Pasteur, Paris, France

**To cite this Article** Schneider, Benoit , Xu, Yingwu , Sellam, Olivier , Sarfati, Robert , Janin, Joel , Véron, Michel and Deville-bonne, Dominique(1999) 'Phosphorylation of Anti-HIV Nucleoside Analogs by Nucleoside Diphosphate Kinase', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 829 — 830

**To link to this Article:** DOI: 10.1080/15257779908041571

**URL:** <http://dx.doi.org/10.1080/15257779908041571>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## PHOSPHORYLATION OF ANTI-HIV NUCLEOSIDE ANALOGS BY NUCLEOSIDE DIPHOSPHATE KINASE

Benoit Schneider<sup>1</sup>, Yingwu Xu<sup>3</sup>, Olivier Sellam<sup>1</sup>, Robert Sarfati<sup>2</sup>,  
Joel Janin<sup>3</sup>, Michel Véron<sup>1</sup> and Dominique Deville-Bonne<sup>1\*</sup>

<sup>1</sup>Unité de Régulation Enzymatique des Activités Cellulaires, CNRS URA1773, Institut Pasteur, Paris France, <sup>2</sup>Unité de Chimie Organique, Institut Pasteur, Paris, France <sup>3</sup>  
Laboratoire d'Enzymologie et de Biochimie Structurales, CNRS UPR 9063,  
91198 Gif-sur-Yvette, France

**ABSTRACT :** The reaction of NDP kinase with antiviral nucleoside triphosphates used in antiviral therapies was studied at the presteady state by fluorescence stopped-flow and compared with the steady-state parameters. The affinity of the analogs was determined by fluorescence titration of a mutated enzyme with an inserted Trp in the binding site. The lack of the 3' hydroxyl in analogs is shown to decrease the  $k_{\text{cat}}$  more than the  $K_D$ .

Nucleoside analogues like AZT (3'deoxy-3'azidothymidine) and ddN (dideoxy-nucleosides) are widely used as antiviral drugs targeted at the HIV reverse transcriptase. The nucleoside analogues must be phosphorylated by cellular kinases. The last step in the pathway leading to the triP-derivative is catalyzed by nucleoside diphosphate (NDP) kinase which is believed to present little specificity towards the nucleobase. The reaction involves the formation of a phosphorylated intermediate according to a ping-pong mechanism. Human and *Dictyostelium* NDP kinases have been resolved by X-ray crystallography and have similar folding with a highly conserved active site<sup>1</sup>.

The presteady-state reaction of *Dictyostelium* NDP kinase with ddNTP was studied by quenching of protein fluorescence after manual mixing or by stopped-flow. The fluorescence signal, which is correlated with the phosphorylation state of the catalytic histidine in the enzyme active site<sup>2</sup>, decreases upon ddNTP addition according to a

monoexponential time course. The pseudo-first order rate constant was determined for different concentrations of the various ddNTPs and was found to be saturable. The data are compatible with a two-step reaction scheme where fast association of the enzyme with the dideoxynucleotide is followed by a rate-limiting phosphorylation step. The rate constants and dissociation equilibrium constants determined for each dideoxynucleotide were correlated with the steady-state kinetic parameters measured in the enzymatic assay in the presence of the two substrates<sup>3</sup>. It is shown that ddNTPs are poor substrates for NDP kinase with a rate of phosphate transfer of 0.02 to 3.5 s<sup>-1</sup> and a K<sub>s</sub> of 1 to 5 mM. The dissociation constants for ADP, GDP, ddADP and ddGDP were also determined by fluorescence titration of a mutant F64W NDP kinase where the introduction of W at the nucleotide binding site provides a direct spectroscopic probe. The lack of the 3'OH in ddNTP causes a ten fold increase in K<sub>D</sub>. Contrary to « natural » NTPs, NDP kinase discriminates between various ddNTPs, with ddGTP the more efficient and ddCTP the least efficient substrate within a range of 100 in k<sub>cat</sub> values<sup>4</sup>.

3'phosphorylated nucleotides are structural analogs of the bound nucleotide to NDP kinase and should be efficient competitive inhibitors. It was shown by fluorescence titration that pApS, a natural nucleotide involved in sulphur metabolism, binds to NDP kinase with a high affinity (K<sub>D</sub> = 10 μM) and indeed inhibits the enzyme activity. The structure of the cocrystal shows a different mode of binding of the nucleotide to the enzyme<sup>5</sup>. PApS is the best NDP kinase inhibitor known so far.

Note: This work was supported in part by grant from the Agence Nationale de la Recherche contre le SIDA »

## REFERENCES

1. Dumas, C.; Lascu, I.; Moréra, S.; Glaser, P.; Fourme, R.; Wallet, V.; Lacombe, M.-L.; Véron, M.; & Janin, J. *EMBO J.*, **1992**, *11*, 3203-3208
2. Deville-Bonne, D.; Sellam, O.; Merola, F.; Lascu, I.; Desmadril, M. & Véron, M. (1996) *Biochemistry*, **1996**, *35*, 14643-14653
3. Bourdais, J.; Biondi, R.; Lascu, I.; Sarfati, S.; Guerreiro, C.; Lascu, I.; Janin, J. & Véron, M. (1996) *J. Biol. Chem.*, **1996**, *271*, 7887-7890
4. Schneider, B.; Xu, Y.; Sellam, O.; Sarfati, R.; Janin, J.; Véron, M. & Deville-Bonne, D. (1998) *J. Biol. Chem.*, **1998**, *273*, 11491-11497
5. Schneider, B.; Xu, Y.; Janin, J.; Véron, M. & Deville-Bonne, D. (1998) *J. Biol. Chem.*, **1998**, in press.